Caring for Medically Unexplained Physical Symptoms after Toxic Environmental Exposures: Effects of Contested Causation

Charles C. Engel Jr.,1,2 Joyce A. Adkins,1 and David N. Cowan1

1Deployment Health Clinical Center, Walter Reed Army Medical Center, Washington, DC, USA; 2Department of Psychiatry, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Medically unexplained physical symptoms (MUPS) are persistent idiopathic symptoms that drive patients to seek medical care. MUPS syndromes include chronic fatigue syndrome, fibromyalgia syndrome, and multiple chemical sensivities. When MUPS occur after an environmental exposure or injury, an adversarial social context that we call “contested causation” may ensue. Contested causation may occur publicly and involve media controversy, scientific disagreement, political debate, and legal struggles. This adversarial social context may diminish the effectiveness of the provider–patient relationship. Contested causation also may occur privately, when disagreement over the causes of MUPS takes place in the patient–provider context. These patient–provider disagreements over causation often occur because of the enigmatic nature of MUPS. We suggest that a context of contested causation may have serious negative effects on healthcare for individuals with MUPS. Context plays a larger role in MUPS care than it does for most medical care because of the uncertain nature of MUPS, the reliance of standard MUPS therapies benefit occupational and military medical patients who are afforded care in the context of contested causation. Key words: chronic fatigue syndrome, environmental, fibromyalgia, Gulf War syndrome, medically unexplained symptoms, military, multiple chemical sensitivity, occupational, somatoform, veterans.

Unexplained Symptoms after Events of Public Health Concern

In the early days of industrialization, risks and hazards were evident to the senses—they could be smelled, touched, tasted or observed with the naked eye. In contrast, many of the major risks today largely escape perception. . . . These risks exist in scientific knowledge rather than everyday experience. — Sociologist Deborah Lupton ([1]; p. 64)

Medically unexplained physical symptoms (MUPS) have been defined as physical symptoms that prompt the sufferer to seek health care but remain unexplained after an appropriate medical evaluation. MUPS are perceptual (a person feels symptoms), cognitive (the person experiencing symptoms decides they are either ominous or benign), and behavioral (e.g., if the person decides the symptoms are ominous, he or she usually seeks healthcare for them). Studies show that MUPS are nearly ubiquitous—conservative estimates suggest that a fourth to a third of physical symptoms in the general population and in primary care settings are medically unexplained (3,4).

Chronic fatigue syndrome (CFS), fibromyalgia syndrome (FMS), and multiple chemical sensitivities (MCS) are among a growing number of symptom syndromes acknowledged as medically unexplained (2,5–13). Several investigators have noted that these and other MUPS syndromes have overlapping phenomenology (2,7,8,12–15), pathophysiology (12), risk factors (7), predictors of outcome (7), and effective therapies (5,7,11). Most argue in various ways that these MUPS syndromes are heterogeneous groupings of symptoms that merge into a single diffuse construct with unclear clinical boundaries—MUPS (6,9). Even though MUPS are unexplained, they are not trivial—they are consistently and strongly associated with impaired functioning, psychosocial distress, and treatable anxiety and depressive disorders (4,16,17).

Epidemiologic studies find that MUPS are so common that we should expect that they would occur after all events or exposures that affect any modest-sized group of people. When MUPS occur after significant events involving environmental exposures, particularly if they are noticeable and impressive, the affected individual often reflects back in search of causes and then links MUPS to these worrisome exposures. This occurs even when the best scientific evidence suggests that a causal relationship is unlikely. Some of the most poignant examples of this have occurred after military or wartime service (18). In the early to mid-1990s, for example, veterans of the Gulf War developed MUPS, leading to questions regarding the possible presence of a Gulf War syndrome due to hazardous battlefield exposures (19). After World War I, many returning veterans described chronic debilitating physical symptoms and attributed them to chemical exposures incurred during months of trench warfare (20). After the Vietnam War, hundreds of thousands of veterans sought evaluation for concerns related to Agent Orange (dioxin) exposure (21).

Other examples in military personnel have occurred outside the context of war. MUPS became a focus of concern following mandated military vaccinations in the United States and United Kingdom (22). MUPS were a concern among Canadian peacekeepers after duty in Croatia, and many linked their symptoms to ruddy soil they encountered at one encampment (23). Apprehension regarding the relationship between low-level depleted uranium exposures and a possible “Balkan War syndrome” recently received worldwide attention (24). In the 1980s Dutch peacekeepers in Cambodia developed
MUPS that became known popularly as “jungle disease” (25).

MUPS after environmental exposures of civilian populations have demonstrated that this issue is larger than military service and war. Examples include the 1979 threat of nuclear accident at Three Mile Island near Harrisburg, Pennsylvania (26), industrial waste exposures at Love Canal in Niagara Falls, New York, in the 1970s (27), exposures to implanted silicone medical devices (28), and possible toxic exposures from a jetliner crash in a populated area of Amsterdam (29). After the 11 September 2001 terrorist attack on the World Trade Center in New York City, concerns of a “WTC syndrome” consisting of cough, indigestion, eye irritation, and other symptoms emerged (30). Follow-up among survivors of the October 2001 anthrax attacks in the United States have uncovered persistent MUPS among handlers of mail that was irradiated to eliminate possible anthrax spores (31,32).

We do not cite these examples in an effort to diminish the medical significance of corresponding environmental exposures. To the contrary, many if not most of these exposure events are known to involve harmful environmental toxins. Instead, in this article we describe how the contentious social context that often follows these exposures may adversely affect healthcare delivery for MUPS. Context has a greater opportunity to directly affect medical care for MUPS than it does for more readily diagnosed diseases. We will show that the impact may be greater because of the uncertain nature of MUPS, the reliance of standard MUPS therapies on a potentially tenuous patient–provider partnership, and the clinical need to rely routinely on subjective MUPS assessments, assessments that often yield discordant patient and provider conclusions about patient health status.

**Social Context, Contested Causation, and Unexplained Symptoms**

In the quotation opening this article, Lupton (1) suggests that today’s major environmental health threats are often imperceptible. MUPS are mysterious in that affected individuals perceive them, but objective evidence proving their existence is elusive. For those who experience MUPS, the symptoms are all too real, and patients with MUPS are generally impatient with anyone who doubts the veracity of their symptom reports. Perhaps, therefore, it is not surprising that patients with MUPS sometimes connect their symptoms to unseen environmental exposures.

Social context may adversely affect the health of patients with MUPS when toxic exposures with plausible health consequences become a matter of media attention, high-profile scientific discussion, political debate, wide-ranging litigation, or doctor–patient disagreement. These relatively adversarial circumstances may be described as “contested causation.” Contested causation may adversely affect MUPS-related healthcare at both the public and private levels. Contested causation is public when it involves population-level stakeholder conflicts. This type of contested causation occurs when scientists publicly disagree over evidence supporting or refuting linkages between MUPS and environmental exposures of wide concern, when large-scale litigation such as class action suits focuses on issues of responsibility and blame for the health effects of environmental exposures, or when political debate involves rancor between polarized adversaries. In publicly contested causation, the popular media often play a large role in disseminating the details of adversarial discussions.

Contested causation is private when patient–provider disagreements regarding cause occur because of the inscrutable nature of MUPS. An extensive literature suggests that in the absence of associated findings on physical examination or clinical testing, providers frequently conclude that MUPS are “minor” and less compelling than when they occur in association with an identifiable disease. In the privacy of the patient–provider relationship, the provider may reject or even directly dispute the patient’s beliefs regarding causation (33). Many providers view MUPS as manifestations of an underlying psychological problem, whereas most patients reporting MUPS find psychological explanations belittling. Different providers, especially those from different medical specialties, may vary widely in their conclusions regarding causation and treatment for a given patient with MUPS. Provider differences can add to patient confusion and possibly increase the likelihood of subsequent patient–provider diagnostic disagreements (34).

Our notion of privately contested causation is partly based on Hadler’s (35) description of an iatrogenic doctor–patient “contest” (as he noted, “It is hard, if not impossible, to get well if you have to prove that you are sick”) (35,36) Brown and colleagues’ (37–39) description of “popular epidemiology” has strongly influenced our conceptualization of publicly contested causation. Brown, a sociologist, described popular epidemiology as the manner in which lay members of environmentally “contaminated communities” (e.g., Love Canal, New York; Woburn, Massachusetts; and U.S. Gulf War veterans—the latter being a community joined by perception of a common experience rather than location) have organized to contest the “dominant epidemiologic paradigm” (i.e., empiricism and scientific authority).

Our concept of contested causation is also developed from Mazur’s (27) inventive use of the movie Breathon, a 1950s depiction of an ancient Japanese fable, to illustrate how different stakeholders involved in Love Canal environmental exposure investigations eventually arrived at equally plausible but markedly different and adversarial perspectives of the same events and studies.

Dembe (40), a sociologist and occupational health services researcher, has performed an extensive historical examination of the social factors determining how occupational illnesses are recognized. He found historical evidence for the impact of social context on the patient–provider relationship, particularly for illnesses involving multifactorial pathogenesis. Dembe pointed out that for illnesses occurring via complex or poorly understood causal pathways, a clinical determination of occupational relatedness is less than straightforward. For example, some causal factors may reside inside but not outside the workplace, other causal factors may reside outside but not inside the workplace, and still other causal factors reside both inside and outside the workplace (40).

The central thesis of this article is that in the context of contested causation, healthcare for MUPS may be adversely affected. These adverse effects of contested causation may manifest in any healthcare setting, are probably greater in occupational and military medical settings, and may affect whether the results of MUPS treatment research studies done in general treatment settings can be generalized to occupational or military settings.

**Patients, Providers, MUPS Treatment, and Symptom-Related Disability**

Alleviating discomfort due to symptoms has long been a central focus of Western medicine. Indeed, relatively few therapies in medicine are curative. Symptoms are a major source of disability among patients with MUPS and those with well-defined diseases (Figure 1) (41), and some have argued that rehabilitative therapies targeting symptom-related disability may provide a model for making systemwide improvements in general healthcare delivery.

---

**Figure 1.** A causal model describing the relationship of biomedical (or disease) status and symptoms to functional status, perceived health, and overall quality of life. Modified from Wilson and Cleary (42).
As Figure 1 suggests, chronic symptoms from any cause (pain is the prototype) can lead to decreased health-related quality of life via at least three mechanisms: a) reduced tolerance for physical activity, b) distress and depressive and anxiety disorders that impair relationships and reduce social functioning, and c) diminished ability to fulfill key roles such as wage earner, spouse, or parent because of decrements in physical and mental health functioning. These mechanisms compound one another, creating a cycle of decreasing functioning, increasing risk factors for poor health (e.g., obesity, hypertension, smoking, drinking, and loss of social supports), increasing incident disease, increasing symptoms, and even causing greater decrements in functioning. Our group has found that MUPS are associated with small but measurable elevations in mortality, even after controlling for a number of potentially confounding mental and substance use disorders (42).

Two rehabilitative therapies (interventions usually based on behavioral principles that are administered to improve functioning and reduce disability), graduated physical activity (GPA) and cognitive-behavioral therapy (CBT), are empirically supported approaches for MUPS and related syndromes (5,11,43–45). The finding to date that different MUPS syndromes respond to similar therapies requires that MUPS after environmental exposures (52,63,64) may be treated early using these modalities.

Most studies have found CBT to be effective for a wide range of MUPS, including FMS, CFS, and irritable bowel syndrome (11,66,67). CBT stems from the theory that symptoms and poor functioning occur because of a complex integration of pathophysiology, cognition, affect, and behavior (68,69). The aim of CBT is 2-fold: a) to facilitate a safe and graduated improvement in functioning without exacerbating symptoms and b) to jointly examine problems and beliefs in an effort to negotiate solutions, identify and revise harmful beliefs, and adopt active coping strategies.

Common components of CBT are time-contingent activity pacing, pleasant activity scheduling, sleep hygiene, assertiveness skills, self-examination for harmful or negative thinking, and structured problem-solving skills. These strategies, alone or in combination, have been used successfully to improve functioning among patients with MUPS and other chronic illnesses (70–78). Figures 2 and 3 summarize this short discussion of rehabilitative approaches to MUPS. Figure 2 explicates key causal pathways by which MUPS lead to reductions in health status. Pathways involving harmful health beliefs and health behaviors are prominent and lead to psychosocial distress and increasing disability. Figure 3 illustrates that CBT and GPA act on all four of these areas, leading to improvements in health status in individuals with MUPS.

The Patient–Provider Relationship in Successful MUPS Care

The success of GPA and CBT hinges on a cooperative patient–provider relationship. Any clinical intervention, of course, calls for providers to help patients change health behaviors. For example, even a simple...
curative therapy such as an antibiotic for a minor infection requires the patient to adhere to a medication prescription. However, persuading a chronically ill patient to embark on a physical activity program or a patient with low back pain (often viewed by the patient as physical disease) to adhere to CBT (often viewed by the patient as “psychotherapy”) requires well-developed provider communication skills and a high level of patient and provider confidence in one another.

Von Korff et al. (79) define collaborative management of chronic illness as “care that strengthens and supports self-care in chronic illness while assuring that effective medical, preventive, and health maintenance interventions take place.” Key elements of collaborative management that they outline include (a) collaborative provider–patient definition of problems; (b) negotiated targeting, goal setting, and planning on the basis of both the importance of the problem and patient motivation and readiness for self-care; (c) creating a continuum of self-management training and support services; and (d) active, sustained follow-up. Components of collaborative self-management training such as GPA and CBT require joint patient–provider negotiations to define goals, priorities, and outcomes of interest. The provider must often inspire and support patients through extended behavioral change. This requires regular follow-up, demonstrations of ongoing provider commitment to the patient, regular reassessment of treatment goals, and joint problem identification and problem solving. Contested causation erodes the foundation for these efforts, the collaborative patient–provider partnership.

Contested Causation and MUPS Care in Occupational and Military Settings

Von Korff et al. recommended a system-level approach to enhancing collaborative care of chronic illness (79). Their recommendations were to: (a) implement performance indicators and incentives that motivate improved care; (b) seek science-based technical assistance to disseminate research findings and effective programs; (c) develop and implement practice guidelines and clinical information systems; and (d) involve employers, community organizations, government, and patient advocacy organizations in efforts to improve care. Since 1994, the U.S. Department of Defense (DoD) healthcare system has pursued this approach to improve health services for MUPS and other postdeployment health concerns. That year, the DoD Comprehensive Clinical Evaluation Program, a diagnostic evaluation and clinical registry, was initiated to address MUPS and other health concerns among Gulf War veterans. In 1999, the DoD effort was expanded to include all military-related health concerns and MUPS, and our group has been at the center of these efforts. At issue, however, is whether there is adequate evidence to conclude that a program of collaborative management for MUPS can succeed in occupational settings such as the military.

In 1995 the DoD established a multifaceted and interdisciplinary center providing rehabilitative care for military personnel reporting persistent and disabling MUPS after Gulf War service (47). The Deployment Health Clinical Center at Walter Reed Army Medical Center in Washington, DC, has since adapted GPA and CBT to the treatment needs of military personnel, veterans, and family members with MUPS (46, 47). Pretreatment–post-treatment data from patients completing this 3-week referral program for MUPS show consistent, modest improvements in participants’ functioning, symptoms, physical health concerns, and psychological distress lasting at least 3 months after treatment (47).

In 1998 the U.S. Department of Veterans Affairs (VA) and the DoD co-sponsored a randomized controlled trial of GPA and CBT, and the study is nearing completion. This study, described in greater detail elsewhere (10), compares 1-year health outcomes for Gulf War veterans with MUPS after 12 weeks of either GPA, CBT, GPA and CBT, or usual care. Twenty sites and nearly 1,100 veterans have enrolled in the study, making it the largest study of GPA and CBT for MUPS to date and the first study to evaluate these strategies in the occupational healthcare setting (10). In 1999 the DoD and VA decided to develop clinical practice guidelines integrating lessons learned since the Vietnam era regarding postdeployment healthcare. The DoD-VA Clinical Practice Guideline on Post-Deployment Health Evaluation & Management (80) and the VA-DoD Clinical Practice Guideline for the Management of Medically Unexplained Symptoms: Chronic Pain and Fatigue (5) are being implemented starting in 2002. Each of these guidelines has its own set of performance indicators to identify implementation successes and gaps. “Tools” (e.g., assessment measures, patient and provider education brochures and videotapes) have been developed facilitating the care prescribed in the guidelines. One guideline tool is the website "PDHealth.mil" (http://www.pdhealth.mil), which is open to the public and provides prompt information on the health effects associated with military-related hazards. Also posted on the site are news media articles that make providers aware of public information available to patients that might cause them to seek medical assistance. Goals of the site are to equip clinicians with near-real-time health information and to foster openness between federal healthcare providers and concerned healthcare system beneficiaries.

In 1999, the Deployment Health Clinical Center became the DoD center of scientific expertise pertaining to postdeployment healthcare delivery. In addition to providing referral clinical services, the center runs continuing health education programs and health services research projects that aim to improve care for MUPS and other military-related health concerns. The center currently has health services research projects under way that are funded by the U.S. National Institutes of Health, the U.S. Centers for Disease Control and Prevention, the DoD, and the VA.

Scientifically valid research to evaluate the effectiveness of these comprehensive federal healthcare programs is a necessity given the concern that contested causation (and perhaps structural influences unique to the federal healthcare system) may subtly erode the provider–patient partnership and above what occurs in the nonoccupational settings where previous MUPS treatment studies have been performed. Next we review possible mechanisms behind this putative erosion.

Threats to Collaborative Management Posed by Contested Causation

Lay people are aware of their dependency on expert knowledges when it comes to disputes about risk. They are also aware of their lack of agency and opportunity, as ‘non-experts,’ to challenge expert knowledges, even if the expert knowledges are uncertain or conflicting. (1, pp. 110–111)

What reasons exist to think that contested causation may adversely affect the care of MUPS? We have illustrated the centrality of the patient–provider relationship in standard MUPS therapies. Historical evidence exists, derived from careful accounts of work-related diseases, that social context can affect the patient–provider relationship, particularly in occupational settings (40). This may occur through any of several overlapping mechanisms.

• Contested causation may erode patient–provider trust, mutual respect, and confidence.
• Contested causation, when mixed with the inherent medical uncertainties surrounding MUPS, may test provider expertise and capacity to share power with affected patients.
• Contested causation, due to inevitable questions of compensation, reparation, and blame, may distract from usual therapeutic goals.

These mechanisms are not mutually exclusive, occur to some degree in all medical
settings, and may have a greater impact in occupational or military healthcare settings. Figure 4 offers a visual model to show how contested causation may reduce the effectiveness of collaborative MUPS management.

**Contested Causation and the Erosion of Trust**

Uncertainty regarding the causation of MUPS provides greater opportunity for disparate patient and provider conclusions regarding legitimate causes. If a patient links his or her MUPS to a contested cause, appropriate provider skepticism may turn instead to overt mistrust of patient motives. Similarly, if a patient perceives (whether correctly or incorrectly) that providers have conflicts of interest that may interfere with their duty to afford them treatment, patient mistrust for those providers may result. For example, the patient may not trust an occupational physician employed by the workplace if the patient perceives that the physician is protecting the employer from liability rather than protecting the workers from medical risk or harm. Another strain on trust that occurs in all healthcare settings but is likely to be amplified in the occupational and military setting is patient fear that the provider may label them with a problem that will follow them in the workplace and endanger their career. MUPS after contested causation, therefore, sometimes work against providers and patients from medical risk or harm.

Another strain on trust that occurs in all healthcare settings but is likely to be amplified in the occupational and military setting is patient fear that the provider may label them with a problem that will follow them in the workplace and endanger their career. MUPS after contested causation, therefore, sometimes work against providers and patients from medical risk or harm.

In the context of contested causation, other insidious sources of patient-provider mistrust may exist. For example, the field of environmental risk communication often teaches that mistrust among concerned parties is heightened in the presence of certain affect-laden “fear factors” related to the characteristics of or circumstances surrounding suspected environmental exposures (81):

- Industrial or man-made exposures (vs. natural exposures)
- Mysterious or poorly understood health problems such as MUPS (vs. better understood diseases such as diabetes mellitus) (81)
- Real or patient-perceived conflicts of provider interest (82)
- Patient history of iatrogenic injury (33, 83)

In the face of news media stories or high-profile political power struggles or legal wrangling, fear factors may contribute to an overtly adversarial provider–patient relationship. Adverse outcomes that result may include reduced patient adherence, increased provider frustration, or even mutual rejection (84).

**Contested Causation, Provider Expertise, and Patient–Provider Power Sharing**

Contested causation and its differential impact on patient and provider explanations for MUPS may create provider–patient conflict and reduce collaboration (85–87). An optimal patient–provider partnership occurs when the patient respects the provider’s medical expertise. Although attitudes are changing, providers remain generally used to relatively unchallenged clinical authority. When patient and provider views differ, however, patients may challenge or question provider opinions, provider skills, or even the provider’s claim to special expertise. For example, a patient may reject a provider’s expert opinion if it conflicts with personal experience (88, 89). If a patient incorrectly concludes that a diagnosis of depression means that the provider believes the patient’s symptoms are imagined, the patient may reject the diagnosis and perhaps the provider because the patient knows with certainty that the symptoms are valid (88). Regarding workplace illness or injury, the patient may feel better informed and more aware of the potential for environmental exposures than a provider who does not deal personally with these risks. These are arguably legitimate patient claims to personal knowledge, given that direct evidence in humans regarding the health effects of many low-dose environmental exposures is sparse, difficult to interpret, and subject to methodological uncertainties.

In the ideal patient–provider partnership, providers must share control of the therapeutic method and value patients’ knowledge of their symptoms. However, in the context of contested causation, these threats to the provider’s traditional role as medical expert and authority can trigger defensive provider responses. Providers may reject patients that challenge them, or they may invoke pathologizing formulations of patients’ personal manner as “difficult” and patients’ MUPS as “psychogenic” (87). In military and occupational settings, administrative pressures to reduce parsimonious explanations for complex patient presentations may further amplify these effects.

**Contested Causation May Distract from Therapeutic Goals**

An effective patient–provider partnership requires both patients and providers to focus attention on improvement of patient functioning. Scientific controversy, political debate, and media attention accompanying contested causation may complicate patient and provider efforts to maintain a consistent focus on therapeutic goals. Often, debates surrounding contested causation implicate “victims” and “oppressors” or “winners” and “losers.” These public debates may distract both patient and provider from therapeutic goals and may affect provider and patient beliefs regarding fairness, entitlements, or need for disability compensation. These provider and patient perspectives may remain unspoken, yet they can still dominate the clinical encounter and distract from efforts to improve patient health (36).

Societal discourse around contested causation, responsibility, blame, and reparation may create predicaments for patients and providers. For example, patients may perceive that “getting well” will risk sending the message to observers that their illness or injury is trivial and therefore that compensation is unneeded. For providers, a common therapeutic goal involves encouraging patient improvements in health behavior and knowledge. However, when compensation is at issue, providers may instead feel more compelled to provide an exact biomedical accounting, even if doing so fails to offer...
disease-specific therapeutic options. For example, providers may explain MUPS as conversion symptoms or a somatoform disorder even though it does not lead to specific therapies and may leave the patient feeling stigmatized.

Treatable and frequently undiagnosed depressive and anxiety disorders often accompany MUPS and compound disability (99). Diagnosing these problems, linking diagnoses to effective therapeutic options, and negotiating acceptable explanations and labels comprise appropriate care. Sometimes, however, contested causation may increase the tendency for providers to adopt psychological explanations for MUPS in an effort to reassure the patient. Patients experiencing MUPS, however, are seldom reassured and often outraged with such explanations. Patients may feel the provider has stolen hope for resolution by blaming them for their symptoms and then failing to offer acceptable treatment.

The other, equally unproductive extreme, may also create distraction. In the context of widely contested causation, the provider may embark on a “no-stone-unturned” search for a disease to explain the patient’s symptoms. Although recognizing the diagnostic yield to be diminishingly small, the provider—altruist may run the test anyway. Paradoxically, this approach may distract the provider and the patient from appropriate treatment. This occurs when the mystery, drama, and hope of the diagnostic process captivate patient and provider, leaving them spectating rather than participating in collaborative management. It may also lead to medically unnecessary patient risk.

A final form of distraction sometimes occurs when the provider believes that publicly contested environmental causation is unscientific, “political,” or frivolous. To prevent “over-utilization” of expensive medical resources in a manner that might nurture ille- gitimate medical fears, the provider may pre-maturely halt the process of care without fostering a patient–provider partnership and negotiating acceptable therapeutic options to reduce disability.

Summary and Conclusions

We have reviewed the notion of MUPS, the overlap of MUPS with several common but poorly understood symptom syndromes, and the predictable occurrence of MUPS after controversial community, occupational, and military exposures. We have asserted, based on an emerging sociologic literature on community exposures and occupational illnesses, that the adversarial social context that often accompanies these environmental exposures, a context we have referred to as “contested causation,” may have an adverse effect on the care of many individuals with MUPS. Factors that allow social context to have a larger role in MUPS care than for many well-defined diseases are the uncertainty of MUPS, the extensive reliance of standard MUPS therapies on a potentially tenuous patient–provider partnership, and the routine need to rely on subjective clinical assessments that are often interpreted differently by the patient than the provider.

Contested causation may adversely affect MUPS care in any medical setting, making it difficult to translate the efficacy of CBT and GPA found in clinical trials into routinely effective clinical practice. Even within a sup-portive healthcare system offering an array of collaborative patient management options, if causation of MUPS is contested publicly (e.g., in the news media) or privately (e.g., during an office visit), concerns regarding dual agency, veracity, and trust often arise and distract from the fundamental goal of improving patient quality of life.

Occupational and military medicine may be more vulnerable to these effects on MUPS care than are other medical systems. Federal medicine has embarked on an ambitious multilayered clinical and policy effort to address military-related MUPS. These efforts include referral programs, clinical practice guidelines, information dissemination strategies, and scientific and clinical centers of excellence. We are playing a central role in these efforts, and we think they are well placed given historical experience suggesting escalating societal and patient concerns about enigmatic MUPS syndromes with potential environmental etiologies. The theoretical probability that contested causation poses additional threat to effective MUPS care in occupational or military settings means that we must demonstrate, wherever possible, the efficacy of MUPS care in these settings using carefully controlled trials.

References and Notes

1. Lupton D. Risk. New York:Routledge, 1999.
2. Engel CC Jr, Katon WJ. Population and need-based prevention of unexplained symptoms in the community: In: Strategies to Protect the Health of Deployed U.S. Forces: Medical Surveillance, Record Keeping, and Risk Reduction (Institute of Medicine). Washington, DC:National Academy Press, 1999;173–212.
3. Kroenke K, Price RK. Symptoms in the community: Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 152(2):2374–2400 (1992).
4. Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deFur VF III, Brody D. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 3(8):774–779 (1994).
5. Veterans Health Administration and Department of Defense. Clinical Practice Guideline for the Management of Medically Unexplained Symptoms: Chronic Pain and Fatigue, 2002. Available: http://www.cs.amhed.army.mil/omp/mux/mux.htm (accessed 17 June 2002).
6. Katon W. Chronic fatigue syndrome criteria. A critique of the requirement for multiple physical complaints. Arch Intern Med 152(8):1604–1609 (1992).
7. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes—one or many? Lancet 354(9182):936–939 (1999).
8. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 134:888–881 (2001).
9. Hyams KC. Developing case definitions for symptom-based conditions: the problem of specificity. Epidemiol Rev 20(2):146–156 (1998).
10. Guarino P, Peduzzi P, Donta ST, Engel CC, Clauw DJ, Williams DA, Skinner JS, Barkhuisen A, Kaza LE, Feusner JR. A multicenter two by two factorial trial of cognitive behavioral therapy and aerobic exercise for Gulf War veterans’ illnesses. Design of a Veterans Affairs Cooperative Study (ESP #430). Control Clin Trials 2000;310–322 (2001).
11. Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychiatr Psychoan 2000;1(3):224–250 (2000).
12. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: over-lapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 4(3):134–153 (1997).
13. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 160(2):221–227 (2000).
14. Hodgson MJ, Kien HM. Gulf War illnesses: causation and treatment. J Occup Environ Med 41(8):443–452 (1999).
15. White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population: A controlled study. Scand J Rheumatol 29(1):44–51 (2000).
16. Katon W, Lin E, von Korff M, Russo J, Lipscomb P, Bush T. Somatization: a spectrum of severity. Am J Psychiatry 148(3):34–40 (1991).
17. Gureje O, Simon GE, Ustun TB, Gordis DP. Somatization in cross-cultural perspective: A World Health Organization study in primary care. Am J Psychiatry 154(7):989–995 (1997).
18. Hyams KC, Wignall FS, Roswell R. War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Ann Intern Med 125(2):196–405 (1996).
19. Institute of Medicine, Committee to Review the Consequences of Service During the Persian Gulf War Medical Follow-up Agency. Health Consequences of Service during the Persian Gulf War: Recommendations for Research and Information Systems. Washington, DC:National Academy Press, 1996.
20. Straus SE. Bridging the gulf in war syndromes. Lancet 353(9144):162–163 (1999).
21. Institute of Medicine. Veterans and Agent Orange: Update 1998. Washington, DC:National Academy Press, 1999.
22. Institute of Medicine. An Assessment of the Safety of the Hazard Mater 76(1):39–58 (2000).
23. Canada National Defence. Final Report: Board of Inquiry—Cuba. Ottawa, ON:National Defence, 2000.
24. Rogers L. Sick troops sue over Balkan War syndrome. Sunday Times of London, News, 16 April 2000.
25. Kaminski M. Dutch government decides to treat battlefield as hazardous workplace. Wall Street Journal, 17 April 2001.
26. Houts P, Cleary P, Hu T. The Three Mile Island Crisis: Psychological, Social, and Economical Impacts on the Surrounding Population. University Park, PA:Pennsylvania State University Press, 1988.
27. Mazur A. A Hazardous Inquiry: The Rashomon Effect at Love Canal. Cambridge, MA:Harvard University Press, 1999.
28. France D. Now, WTC syndrome? Newsweek, 5 November 1998.
29. Uijt de Haag PA, Smetsers RC, Witlox HW, Krus HW, Eisenga AH. Evaluating the risk from depleted uranium after the Boeing 747–258F crash in Amsterdam, 1992. J Hazard Mater 76(1):39–58 (2000).
30. France D. Now, WTC syndrome? Newsweek, 5 November 1998.
31. France D. Now, WTC syndrome? Newsweek, 5 November 1998.
43. Working Group of the Royal Australasian College of Physicians. Chronic fatigue syndrome. Clinical practice guidelines—2002. Med J Aust 176:S17–S56 (2002).
44. Dembe AE. Occupation and Disease. How Social Factors Affect the Conception of Work-Related Disorders. New Haven, CT:Yale University Press, 1996.
45. Wilson IB, Cleary PD. Linking clinical variables with health status: 2-year follow-up of a randomised controlled trial. Br Med J 312(7022):22–26 (1996).
46. Richardson RD, Engel CC Jr, Roy M, Kayanan D, Ursano R. Multidisciplinary treatment of persistent symptoms after Gulf War service. Mil Med 163(4):202–208 (1998).
47. Reid S, Chalder T, Marks I, Wessely S. Cognitive behaviour therapy for chronic fatigue syndrome: a randomized controlled trial. Br Med J 312(7022):22–26 (1996).
48. McCully KK, Sista SA, Nateson BH. Use of exercise for treatment of chronic fatigue syndrome. Sports Med 21(1):35–48 (1996).
49. Weyerer S, Kupfer B. Physical exercise and psychological health. Sports Med 17(2):108–116 (1994).
50. Krupp LB, Petre Y, Michaud K, Dandurand J. Fatigue: a new clinical syndrome? Analysis of the relationship between multiple idiopathic unexplained symptoms and quality of life. JAMA 269:1398–1403 (1993).
51. Krupp LB, Kraines R, Steinberg G, Benson K. The FCFS pain and fatigue questionnaire: validation and psychometric properties. J Rheumatol 23(1):176–180 (1996).
52. Wiers GH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol 35(2):17–21 (1996).
53. Klimes I, Peto T, Warrell D, Seagroatt V. Cognitive behaviour therapy for chronic fatigue syndrome. Br Med J 314(7095):1647–1652 (1997).
54. Sonstroem RJ. Exercise and self-esteem. Exerc Sport Sci Rev 12:123–155 (1984).
55. Mannerkorpi K, Nyberg B, Ahlmen M, Ekdahl C. Pool exercise and treatment of fibromyalgia syndrome: a prospective, randomized study. J Rheumatol 21(7):2473–2481 (2000).
56. Furner SI, Audenaert F, Morgan S, Goadsby PJ, Vinken PJ. The efficacy of exercise programmes in the treatment of episodic and chronic cluster headache. J Neurol Neurosurg Psychiatry 64(3):165–170 (1998).
57. Price JR, Couper J. Cognitive behaviour therapy for chronic fatigue syndrome in adults [Cochrane Review]. In: The Cochrane Library, Issue 2, 2002. Oxford, UK:Update Software.
58. Turk DC, Meichenbaum D, Genetis M. Pain and Behavioral Medicine: A Cognitive-Behavioral Perspective. New York:Guilford Press, 1983.
59. McCann L, Holmes DA. Influence of aerobic exercise on depression. J Pers Soc Psychol 46:1124–1143 (1984).
60. Wallberg-Henriksson H, Rincon J, Zethraeus J. Exercise in the management of non-insulin-dependent diabetes mellitus. Sports Med 25(1):25–35 (1998).
61. Eldar R, Marinicke C. Physical activity for elderly persons with neurological impairment: a review. Scand J Rehabil Med 32(3):99–103 (2000).
62. Corner J, Plant H, A’Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 14(4):290–295 (2000).
63. Bucklewe SP, Conway R, Parker J, Deuser WE, Read J, Witty TE, Hewett JW, Minor M, Johnson JC, Van Maale J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res 11(2):196–209 (1998).
64. Fulcher KY, White PD. Randomized controlled trial of graded exercise in patients with the chronic fatigue syndrome. Br Med J 314(7095):1647–1652 (1997).
65. Mannerkorpi K, Nyberg B, Ahlmen M, Ekdahl C. Pool exercise combined with an education program for patients with fibromyalgia syndrome: A prospective, randomized study. J Rheumatol 21(7):2473–2481 (2000).
66. Martin J, Nutting A, Macintosh BR, Edworthy SM, Butterwick D, Cook J. An exercise program in the treatment of fibromyalgia. J Rheumatol 26(8):1505–1508 (1999).
67. Wearden AJ, Morris RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IJ, Morris JA. Randomised, double-blind, placebo-controlled trial of treatment of fibromyalgia syndrome. Br J Sports Med 32:1485–1490 (1998).
68. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol 35(2):17–21 (1996).
69. Janol MN. Pain sensitivity, exercise, and stoicism. J Soc Med 89(7):376–381 (1996).
70. Sontrom RJ. Exercise and self-esteem. Exerc Sport Sci Rev 12:123–155 (1984).
71. Hammett VBO. Psychological changes with physical fitness training. Can Med Assoc J 96(12):784–788 (1967).
72. Mengshoel AM, Vollset KE, Forre O. Pain and fatigue induced by exercise in fibromyalgia syndrome and sedentary healthy subjects. Clin Exp Rheumatol 22:17–21 (1994).
73. Gil KM, Wilson JJ. The efficacy of psychological and pharmacological interventions for the treatment of chronic disease-related and non-disease related pain. Clin Psychol Rev 16:573–597 (1996).
74. Quill TE. Somatization disorder. One of medicine’s blind spots. JAMA 252(21):2986–2987 (1984).
75. Bennet P. Understanding responses to risk: some basic findings. In: Risk Communication and Public Health (Bennet P, Calman K, eds). New York:Oxford University Press, 1993:19–33.
76. Mechanic D. The functions and limitations of trust in the provision of medical care. J Health Pol Policy Law 23:681–698 (1998).
77. Krauswold K, Pither CE, Rabe-Hesketh S, Wessely S. A comparative study of iritrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Pain 76(3):417–426 (1998).
78. NIH Technology Panel. Integration of behavioral and psychosocial therapies into the treatment of chronic pain and insomnia. JAMA 276(13):318–319 (1996).
79. Thomas JD, LaRochelle KL, Weltzien EK, Krupp LB, Schumacher HR. Multisystemic treatment of adolescent boys with unexplained symptoms. J Am Acad Child Adolesc Psychiatry 38(7):781–792 (1999).
80. Von Korff M, Gruman J, Spaeder C, Curry SJ, Wagner EH. Collaborative management of chronic illness. Ann Intern Med 121(12):1097–1102 (1997).
81. Department of Defense and Veterans Health Administration. Clinical Practice Guideline on Post-deployment Health Evaluation & Management (2002). Available: http://www.adhealhth.mil/PDHEM/ToolKit/download2/guideline1.exe (accessed 17 June 2002).
82. Bennet P. Understanding responses to risk: some basic findings. In: Risk Communication and Public Health (Bennet P, Calman K, eds). New York:Oxford University Press, 1993:19–33.
83. Mechanic D. The functions and limitations of trust in the provision of medical care. J Health Pol Policy Law 23:681–698 (1998).
84. Koyoumaz K, Pither CE, Rabe-Hesketh S, Wessely S. A comparative study of iritrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Pain 76(3):417–426 (1998).
85. Quill TE. Somatization disorder. One of medicine’s blind spots. JAMA 252(21):2986–2987 (1984).
86. Lin EH, Katon W, Von Korff M, Bush T, Lipscomb P, Russo J, Wagner E. Frustrating patients: physician and patient perspectives among distressed high users of medical services. J Gen Intern Med 63:241–246 (1991).
87. Walker EA, Katon WJ, Keegan D, Gardner G, Sullivan M. Predictors of physician frustration in the care of patients with rheumatological complaints. Gen Hosp Psychiatry 19(3):235–238 (1997).
88. Hahn SR, Thompson KS, Willis TA, Stern V, Budner NS. The difficult doctor-patient relationship: somatization, personality and psychopathology. J Clin Epidemiol 47:647–657 (1994).
89. Salmon P, Peters S, Stanley I. Patients’ perceptions of medical explanations for somatisation disorders: qualitative analysis. Br Med J 318(7180):372–376 (1999).
90. Engell CC Jr, Kroenke K, Katon WJ. Mental health services in Army primary care: the need for a collaborative health care agenda. Mil Med 158(3):203–209 (1994).